July 30, 2011 -- Boston Scientific will spend $150 million in China over the next five years to increase revenues in the PRC; Shares of Shijiazhuang Yiling Pharma climbed 27% following the company’s ChiNext IPO; Shanxi C&Y Pharma received regulatory approval to IPO on Shenzhen’s ChiNext exchange; Meheco Corporation will gain a controlling stake in Xinjiang Tianshan Pharma via a two-step process; Aeras signed a MOU with the China National Biotech Group (CNBG) to develop inexpensive, effective TB vaccines; Hutchison China MediTech will form a JV to offer third-party OTC drug distribution; Shenzhen Hepalink Pharma said 2011 first-half results were hurt by higher costs and lower revenues; and researchers from Shenzhen’s BGI published data showing the importance of structural variations in genomes for individual diversity. More details….
Stock Symbol: (NYSE: BSX) (SHE: 002603) (SHA: 600056) (AIM: HCM) (SHE: 002399)
